COMPANY:

bioAffinity Technologies

"bioAffinity Technologies, Inc...today announced continued sales growth of its noninvasive lung cancer diagnostic test, CyPath® Lung, with the number of tests processed increasing steadily each month and more than doubling since the start of 2025. October’s test volume increased by 111% over the 2025 monthly average."

"bioAffinity Technologies, Inc...today announced it will present research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The study supports the methods used to collect and transport patient samples for analysis by the Company’s noninvasive CyPath® Lung test for detecting early-stage lung cancer."

"U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Technologies’ CyPath® Lung in its pulmonary issue, highlighting the test’s potential to improve lung cancer detection while lowering costs for the Department of Veterans Affairs (VA)."

"bioAffinity Technologies, Inc...today announced a significant surge in commercial sales of its flagship product, CyPath® Lung, a noninvasive diagnostic for early-stage lung cancer."

"bioAffinity Technologies, Inc...today shared another compelling patient case study in which its flagship test, CyPath® Lung, detected pulmonary mucinous adenocarcinoma in a high-risk individual whose previous tests and follow-up scans had suggested a low probability of cancer that could have led to diagnosis at a later, less treatable stage."

"bioAffinity Technologies, Inc...today released a compelling new case study in which CyPath® Lung identified a Stage 1A neuroendocrine tumor in the patient’s lung after PET scan, bronchoscopies and a serum tumor marker test suggested it was non-cancerous inflammation."

"bioAffinity Technologies, Inc...today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company’s diagnostic platform that powers its flagship test, CyPath® Lung."

"bioAffinity Technologies, Inc...today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry."

"bioAffinity Technologies...today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung cancer in a patient whose PET imaging and risk model probability indicated a low risk of malignancy."

"bioAffinity Technologies...will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company’s recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property Administration."

"bioAffinity Technologies...announced the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering a novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The patent, 'Compositions and Methods for Treating Cancer,' (Patent No. 12,305,171) provides for use of the novel therapeutic approach with cancers of the lung, breast, prostate, brain and skin. Research has begun toward development of a topical treatment for cutaneous malignancies and neoplasms of the skin."

"bioAffinity Technologies, Inc...today announced the release of a white paper authored by Dr. Gordon Downie, MD, PhD, Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center.The paper, titled “CyPath® Lung in Practice: Cases 1-4,” details real-world clinical cases in which CyPath® Lung, a noninvasive sputum-based test, significantly influenced clinical decision-making for patients with indeterminate pulmonary nodules."